Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | GeneticVariation | BEFREE | Recent works have studied the prognostic significance of WT1 polymorphisms and mutations, highlighting the role of SNP rs16754 as a positive prognostic factor in AML patients. | 29407184 | 2018 |
||||
|
0.100 | GeneticVariation | BEFREE | The single-nucleotide polymorphism (SNP) within Wilms tumor-1 (WT1) exon 7, rs16754, has been arguably reported to be implicated in acute myeloid leukemia (AML) prognosis. | 26499507 | 2016 |
||||
|
0.100 | GeneticVariation | BEFREE | A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia. | 26644203 | 2016 |
||||
|
0.100 | GeneticVariation | BEFREE | In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. | 26992216 | 2016 |
||||
|
0.100 | GeneticVariation | BEFREE | Wilms tumor gene single nucleotide polymorphism (WT1 SNP) rs16754 has been described as a favorable risk marker in patients with acute myeloid leukemia. | 26224397 | 2015 |
||||
|
0.100 | GeneticVariation | BEFREE | The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients. | 25932444 | 2015 |
||||
|
0.100 | GeneticVariation | BEFREE | In summary, WT1 rs16754 may serve as an independent biomarker in AML patients from South Chinese. | 25841655 | 2015 |
||||
|
0.100 | GeneticVariation | BEFREE | In summary, WT1 rs16754 and WT1 expression have a significant impact on clinical outcome in patients with AML. | 23550990 | 2014 |
||||
|
0.100 | GeneticVariation | BEFREE | The Wilms' tumour gene 1 (WT1) single nucleotide polymorphism (SNP) rs16754 has recently been described as an independent prognostic factor in acute myeloid leukaemia (AML) patients. | 23484026 | 2013 |
||||
|
0.100 | GeneticVariation | BEFREE | We were unable to confirm the suggested favorable outcome of SNP rs16754 in de novo AML. | 23070125 | 2012 |
||||
|
0.100 | GeneticVariation | BEFREE | Four-hundred and thirty-three intensively treated and molecularly characterized cytogenetically normal patients with de novo acute myeloid leukemia (18-83 years old) were analyzed for rs16754. | 21659357 | 2011 |
||||
|
0.100 | GeneticVariation | BEFREE | The frequency of WT1 mutation in the Southeast Asian AML was thus comparable to the figures reported from the West although the designated major allele for rs16754 polymorphism was different. | 21798259 | 2011 |
||||
|
0.100 | GeneticVariation | BEFREE | To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML). | 21189390 | 2011 |
||||
|
0.010 | GeneticVariation | BEFREE | In conclusion, WT1 normal gene variant rs2234593 is associated with mutational status of WT1 Ex7 and is a further prognostic marker independent from FLT3-ITD and NPM1 mutations in NK-AML. | 26499507 | 2016 |